US EditionEli Lilly Obesity Drug Mounjaro Beats Legacy Trulicity On Cardio-Renal Health - Eli Lilly (NYSE:LLY)
GLOBAL, JUL 31 – Mounjaro reduced cardiovascular death risk by 8% and all-cause mortality by 16% compared to Trulicity in a large, nearly five-year trial involving over 13,000 patients.
- On Thursday, Eli Lilly announced its diabetes drug Mounjaro showed heart health benefits in a SURPASS-CVOT Phase 3 trial versus Trulicity.
- The SURPASS-CVOT trial enrolled more than 13,000 participants over four and a half years and is expected to wrap up in 2027.
- The trial showed Mounjaro reduced the risk of cardiovascular events by 8% and lowered the all-cause mortality rate by 16% compared to Trulicity.
- Following the results announcement, Eli Lilly shares fell 1.40% to $749.45 in premarket trading while clinicians favor Mounjaro.
- Lilly plans to submit the heart health data to global regulators by the end of the year and could see approval in 2026 to extend Mounjaro indications.
Insights by Ground AI
Does this summary seem wrong?
17 Articles
17 Articles
Coverage Details
Total News Sources17
Leaning Left2Leaning Right0Center6Last UpdatedBias Distribution75% Center
Bias Distribution
- 75% of the sources are Center
75% Center
L 25%
C 75%
Factuality
To view factuality data please Upgrade to Premium
